Is EOLS or ESPR more undervalued in 2026?

CirclFi compares Evolus, Inc. Common Stock (EOLS) and Esperion Therapeutics, Inc. (ESPR) using 13 institutional-grade valuation models. EOLS has a Quality of Company score of 5.9/10 while ESPR scores 5.2/10.

Which is a better buy — EOLS or ESPR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EOLS and ESPR valuations compare?

EOLS at $6.57 and ESPR at $3.13 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EOLS vs ESPR Valuation Comparison 2026 — Intrinsic Value Analysis

EOLS

Drug Manufacturers - Specialty & Generic

Evolus, Inc. Common Stock

Quality

5.9

out of 10

Value Trap

LOW

Price

$6.57

Last close

Models

10/13

Active

ESPR

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc.

Quality

5.2

out of 10

Value Trap

LOW

Price

$3.13

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	EOLS Fair Value	EOLS Upside	ESPR Fair Value	ESPR Upside
Bayesian DCF	Intrinsic	$1.14	-82.6%	$1.09	-65.0%
Earnings Power Value	Intrinsic	$3.70	-30.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$4.79	-27.0%	$2.33	-25.7%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EOLS vs ESPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EOLS vs ESPR — Which Stock Is More Undervalued?

EOLS scores higher with a 5.9/10 quality rating vs ESPR's 5.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evolus, Inc. Common Stock (EOLS) and Esperion Therapeutics, Inc. (ESPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EOLS currently trades at $6.57 with a QOC of 5.9/10, while ESPR trades at $3.13 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).